Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Signalling Pathways 2017

The programme for the ESMO Symposium on Signalling Pathways in Cancer 2017 is now online!

View the Programme Online Download the Programme (PDF)

Major themes

  • DNA damage response
  • DNA damage landscape in tumours according to mutational status, DNA damaging agents, immune reactions
  • Mechanisms of pathways conferring resistance to DNA damage and how to circumvent such pathways
  • Review of the present data from DNA Damaging Agents Repairs Inhibitors (PARP, ATR, DNA-PK, APE)

Learning objectives

  • To provide a basic introduction on the preclinical data relevant for understanding of functional aspects of DNA damage and repair mechanisms
  • To understand basic concepts of translating preclinical data in the DNA damage and how cancer cells survive DNA damage through repair mechanisms
  • To provide an essential update on different approaches to block DNA repair and overcome resistance to DNA damaging therapies
  • To elaborate from the clinical perspective therapeutic strategies from recent achievements

Benefits of attending

  • The programme is designed to accelerate the pace of translating novel and emerging cancer treatments to the bedside
  • The lectures are designed to meet high educational standards and make an impact on personalised cancer therapy approaches
  • An expert faculty will strive to enhance understanding of this signalling pathway and the complexities related to its targeting in a range of tumor types
  • The relatively small size of the event will offer maximum networking opportunities

CME Accreditation

ESMO-MORA: The programme of the Symposium has been accredited with 11 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. Find out more about ESMO-MORA accreditation.

CME: The Symposium is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), uems.net

The Symposium is designated for a maximum of 9 hours of European external CME credits. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Find out how to convert EACCME credit to AMA credit.


The Symposium webcasts will include all the session of the official programme, where speaker permission is granted, and will be available on this website and OncologyPRO for ESMO members.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings